MX358502B - Anticuerpo quimerico terapeutico anti-cd37 hh1. - Google Patents

Anticuerpo quimerico terapeutico anti-cd37 hh1.

Info

Publication number
MX358502B
MX358502B MX2014006998A MX2014006998A MX358502B MX 358502 B MX358502 B MX 358502B MX 2014006998 A MX2014006998 A MX 2014006998A MX 2014006998 A MX2014006998 A MX 2014006998A MX 358502 B MX358502 B MX 358502B
Authority
MX
Mexico
Prior art keywords
antibodie
present
therapeutic anti
chimeric therapeutic
applications
Prior art date
Application number
MX2014006998A
Other languages
English (en)
Other versions
MX2014006998A (es
Inventor
H Larsen Roy
Dahle Jostein
Original Assignee
Nordic Nanovector As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordic Nanovector As filed Critical Nordic Nanovector As
Publication of MX2014006998A publication Critical patent/MX2014006998A/es
Publication of MX358502B publication Critical patent/MX358502B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una molécula de anticuerpo que se une a un CD37 humano y que es un anticuerpo quimérico caracterizado porque se define mediante i) una cadena pesada variable que comprende la secuencia de aminoácidos que se muestra en la SEQ ID NO: 1; y ii) una cadena ligera variable que comprende la secuencia de aminoácidos que se muestra en la SEQ ID NO: 3, iii) cadenas ligeras y pesadas constantes que son de origen humano; en donde las cadenas pesadas constantes i) comprende secuencias de aminoácidos codificadas por las secuencias de ácidos nucleicos mostradas en las SEQ ID NO: 5, SEQ ID NO: 6 y SEQ ID NO: 7, y en donde dicha cadena ligera constante ii) comprende una secuencia de aminoácido codificada por la secuencia de ácido nucleico mostrada en la SEQ ID NO: 9.
MX2014006998A 2011-12-13 2012-12-12 Anticuerpo quimerico terapeutico anti-cd37 hh1. MX358502B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161569981P 2011-12-13 2011-12-13
PCT/IB2012/057230 WO2013088363A1 (en) 2011-12-13 2012-12-12 Chimeric therapeutic anti - cd37 antibodie hh1

Publications (2)

Publication Number Publication Date
MX2014006998A MX2014006998A (es) 2015-02-20
MX358502B true MX358502B (es) 2018-08-23

Family

ID=47603883

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006998A MX358502B (es) 2011-12-13 2012-12-12 Anticuerpo quimerico terapeutico anti-cd37 hh1.

Country Status (17)

Country Link
US (2) US20140348745A1 (es)
EP (2) EP3272364B1 (es)
JP (1) JP2015501654A (es)
KR (1) KR20140103140A (es)
CN (2) CN104114192A (es)
AU (1) AU2012354140B2 (es)
BR (1) BR112014014258A2 (es)
CA (1) CA2858964A1 (es)
ES (1) ES2827787T3 (es)
HK (1) HK1203372A1 (es)
IL (1) IL233084A (es)
MX (1) MX358502B (es)
PH (1) PH12014501338A1 (es)
PL (1) PL3272364T3 (es)
RU (1) RU2658438C2 (es)
SG (1) SG11201403134PA (es)
WO (1) WO2013088363A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012023010A8 (pt) 2010-03-12 2017-12-26 Immunogen Inc Anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37
JP6335284B2 (ja) * 2013-06-07 2018-05-30 ノルディック ナノベクター エーエスエー 抗原発現を上方制御するための方法
AU2014296219A1 (en) 2013-08-01 2016-02-25 Agensys, Inc. Antibody drug conjugates (ADC) that bind to CD37 proteins
US9433690B1 (en) 2015-02-26 2016-09-06 Sciencons AS Radiopharmaceutical solutions with advantageous properties
US20170000900A1 (en) 2015-06-08 2017-01-05 Immunogen, Inc. Anti-cd37 immunoconjugate and anti-cd20 antibody combinations
EP3341414A4 (en) 2015-08-28 2019-03-27 Debiopharm International SA ANTIBODIES AND ASSAYS FOR DETECTION OF CD37
GB201600328D0 (en) 2016-01-08 2016-02-24 Univ Oslo Hf Anti-CD37 chimeric antigen receptors and immune cells expressing them
SG10202102588QA (en) * 2016-09-16 2021-04-29 Nordic Nanovector Asa Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan
WO2018083633A1 (en) 2016-11-02 2018-05-11 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
AU2018207190B2 (en) * 2017-01-12 2020-12-03 Orano Med Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
CN111372613A (zh) * 2017-11-22 2020-07-03 诺帝克纳诺维科特公司 放射免疫缀合物与其他药物联合治疗非霍奇金淋巴瘤
AR125130A1 (es) * 2021-03-19 2023-06-14 Heidelberg Pharma Res Gmbh Conjugados de amatoxina y anticuerpo específicos de linfocitos b
WO2023054285A1 (ja) * 2021-09-29 2023-04-06 国立大学法人大阪大学 α線放出抗体薬物複合体
WO2023057595A1 (en) * 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
WO2023057583A1 (en) * 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1
CA3235358A1 (en) * 2021-10-18 2023-04-27 Daiichi Sankyo Company, Limited Anti-cd37 antibody-drug conjugate
WO2023133488A1 (en) * 2022-01-06 2023-07-13 The General Hospital Corporation Methods of cell ablation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
RU2139351C1 (ru) * 1991-04-25 1999-10-10 Чугаи Сейяку Кабусики Кайся Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности
TWI381050B (zh) * 2005-03-31 2013-01-01 Biomedics Inc Anti-CD20 monoclonal antibody
ES2460517T3 (es) * 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
PE20120259A1 (es) * 2007-08-09 2012-04-04 Boehringer Ingelheim Int Anticuerpos anti-cd37
TW201031749A (en) * 2009-02-10 2010-09-01 Otsuka Chemical Co Ltd IgG-Fc fragment and method for manufacturing the same
NO331080B1 (no) * 2010-01-29 2011-09-26 Nordic Nanovector As Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
BR112012023010A8 (pt) * 2010-03-12 2017-12-26 Immunogen Inc Anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37

Also Published As

Publication number Publication date
NZ626188A (en) 2016-12-23
US20140348745A1 (en) 2014-11-27
EP2790740A1 (en) 2014-10-22
MX2014006998A (es) 2015-02-20
RU2014125320A (ru) 2016-02-10
HK1203372A1 (en) 2015-10-30
SG11201403134PA (en) 2014-07-30
AU2012354140A1 (en) 2014-07-03
ES2827787T3 (es) 2021-05-24
WO2013088363A1 (en) 2013-06-20
CN104114192A (zh) 2014-10-22
KR20140103140A (ko) 2014-08-25
IL233084A0 (en) 2014-08-03
RU2658438C2 (ru) 2018-06-21
IL233084A (en) 2017-06-29
BR112014014258A2 (pt) 2020-10-27
JP2015501654A (ja) 2015-01-19
PL3272364T3 (pl) 2021-04-06
PH12014501338A1 (en) 2014-09-15
US20180194852A1 (en) 2018-07-12
CA2858964A1 (en) 2013-06-20
CN109276713A (zh) 2019-01-29
EP3272364B1 (en) 2020-07-29
EP3272364A1 (en) 2018-01-24
AU2012354140B2 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
PH12014501338A1 (en) Chimeric therapeutic anti-cd37 antibodie hh1
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
HK1217498A1 (zh) 使用人源化抗 嵌合抗原受體治療癌症
IN2014KN00848A (es)
SG194701A1 (en) Anti-cd40 antibodies and methods of use
TN2012000462A1 (en) Anti-cd40 antibodies
NZ707086A (en) Anti-cd40 antibodies and methods of use
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
MX2013009362A (es) Anticuerpo contra el csf-1r.
PH12014502406B1 (en) Anti-il-23p19 antibodies
MX2016008098A (es) Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso.
PH12017500864A1 (en) Anti-notch1 antibodies
UA116873C2 (uk) Антитіло, яке зв'язується з ox40
MY173377A (en) Anti-b7-h3 antibody
TN2014000107A1 (en) Anti-aplhabetatcr antibody
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
PL2550296T3 (pl) Przeciwciała monoklonalne w leczeniu nowotworów
EP2670435A4 (en) USE OF ANTI-DKK1 MONOCLONAL ANTIBODY FOR THE TREATMENT OF LIVER CANCER
PH12015501360A1 (en) Bmp-6 antibodies
BR112013003257A2 (pt) anticorpos egfr humanizados.
MX2015008534A (es) COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS.
WO2012026878A8 (en) Monoclonal antibody specific to major neutralizing epitope of influenza h5 hemagglutinin
EA201390117A1 (ru) Композиция антител к vegfr-3

Legal Events

Date Code Title Description
FG Grant or registration